700 patients109,892 observations180 daysLIVE

DeepGene damage signature

SyntheticSynthetic demo data2 samples: baseline day 0 · retest day 90
Damage score · retest day 90
24/100
vs baseline (day 0)
+4
3 improved · 2 worsened
synthetic signature · consistent with this patient's biology
  • 2 opportunists above range: Escherichia coli, Klebsiella pneumoniae
  • 1 keystone species absent
  • 2 resistance genes
  • Host DNA fragmentation atypical
Pathogens / opportunists2/5
from 3
Keystone species1/8
Diversity0/2
Metabolic modules0/4
Vitamin synthesis1/7
Oral translocation0/1
Host DNA1/1
from 0
Tissue recycling0/1
Central mechanisms0/2
Virulence factors1/1
Antibiotic resistance genes2/2
from 3
Genetic predisposition2/2
Opportunists above range
Escherichia coli 6.912% AR
Klebsiella pneumoniae 2.073% AR
Keystone species absent
Akkermansia muciniphila
Capacity
Shannon 3.43 · butyrate 800 CPM · SCFA 1313
1 vitamins below
Host & mechanisms
host DNA fragmentation atypical
tissue recycling 25/100
oral translocation 1.61% AR
2 resistance genes · 1 virulence factors
Import a sample

A baseline sample re-initializes this patient's microbiome, pathways and predispositions from the measurement; a retest adds a comparison and updates them. Every theory, steering gain and dietary sensitivity downstream is then conditioned on the measured signature.

All elements · baseline → latest
Value, status vs the expected range, and the implication on health. Changes coloured: green improved / resolved, red worsened / new.
Pathogens / opportunists · 5
Escherichia coli5.524 % AR · above range6.912 % AR · above rangeexpected <= 1%In excess raises LPS load and zonulin release, opening tight junctions.
Klebsiella pneumoniae0.041 % AR · in range2.073 % AR · above range(worsened)expected <= 0.3%Opportunist above range; relevant after antibiotics and in inflammation.
Enterococcus faecium0.153 % AR · in range0.17 % AR · in rangeexpected <= 0.5%Opportunist above range; relevant after antibiotics and in inflammation.
Streptococcus gallolyticus0.552 % AR · above range0.032 % AR · in range(improved)expected <= 0.1%Opportunist above range; relevant after antibiotics and in inflammation.
Clostridioides difficile0.552 % AR · above range0.025 % AR · in range(improved)expected <= 0.1%Opportunist above range; relevant after antibiotics and in inflammation.
Keystone species · 8
Akkermansia muciniphila0 % AR · absent0 % AR · absentexpected 0.15-2.24%Keystone butyrate producer / mucin specialist.
Bifidobacterium longum0.19 % AR · in range0.73 % AR · in rangeexpected 0.15-2.24%Keystone butyrate producer / mucin specialist.
Butyricicoccus pullicaecorum0.75 % AR · in range1.03 % AR · in rangeexpected 0.15-2.24%Keystone butyrate producer / mucin specialist.
Eubacterium rectale0.93 % AR · in range0.88 % AR · in rangeexpected 0.15-2.24%Keystone butyrate producer / mucin specialist.
Faecalibacterium prausnitzii1.22 % AR · in range1.17 % AR · in rangeexpected 0.15-2.24%Keystone butyrate producer / mucin specialist.
Lactobacillus species0.14 % AR · in range0.21 % AR · in rangeexpected 0.15-2.24%Keystone butyrate producer / mucin specialist.
Roseburia intestinalis0.32 % AR · in range0.8 % AR · in rangeexpected 0.15-2.24%Keystone butyrate producer / mucin specialist.
Ruminococcus bromii0.78 % AR · in range0.45 % AR · in rangeexpected 0.15-2.24%Keystone butyrate producer / mucin specialist.
Diversity · 2
indice Shannon3.37 · in range3.43 · in rangeexpected >= 3.0Low diversity: fewer reserve metabolic routes, slower recovery after perturbation.
numar de specii detectate161 specii · in range145 specii · in rangeexpected >= 100Species count below reference.
Metabolic modules · 4
Butyrate production842 CPM · in range800 CPM · in rangeexpected 255.83-1089.91 CPMButyrate is the main colonocyte fuel and barrier signal.
Short Chain Fatty Acid Production1312 CPM · in range1313 CPM · in rangeexpected 535.03-1572.59 CPMTotal SCFA capacity.
GABA production464 CPM · in range456 CPM · in rangeexpected 87.31-766.53 CPMGut–brain axis capacity.
H2S production (sulfate reduction)105 CPM · in range119 CPM · in rangeexpected banda de referintaHydrogen sulfide above band irritates the mucosa.
Vitamin synthesis · 7
Vitamin B1 - Thiamin197 CPM · below range404 CPM · below rangeexpected 2000-5000 CPMMicrobial synthesis capacity.
Vitamin B2 - Riboflavin3503 CPM · in range2876 CPM · in rangeexpected 2000-5000 CPMMicrobial synthesis capacity.
Vitamin B5 - Pantothenic acid3395 CPM · in range3936 CPM · in rangeexpected 2000-5000 CPMMicrobial synthesis capacity.
Vitamin B6 - Pyridoxine3401 CPM · in range4308 CPM · in rangeexpected 2000-5000 CPMMicrobial synthesis capacity.
Vitamin B7 - Biotin2934 CPM · in range4412 CPM · in rangeexpected 2000-5000 CPMMicrobial synthesis capacity.
Vitamin B9 - Folate4222 CPM · in range3747 CPM · in rangeexpected 2000-5000 CPMMicrobial synthesis capacity.
Vitamin B12 - Cobalamin3374 CPM · in range3917 CPM · in rangeexpected 2000-5000 CPMMicrobial synthesis capacity.
Oral translocation · 1
Translocare orala (indice)1.29 % AR · in range1.61 % AR · in rangeexpected <= 2%Oral taxa in stool: reduced gastric barrier or dysbiosis.
Host DNA · 1
fragmentare mixta160 pb · in range208 pb · atypical(worsened)expected 150-170 pbHost cell-free DNA fragmentation pattern.
Tissue recycling · 1
indice de reciclare tisulara28 /100 · in range25 /100 · in rangeexpected < 35Epithelial turnover.
Central mechanisms · 2
molecular_mimicry48 /100 · in range55 /100 · in rangeexpected < 65Cross-reactive antigen load.
estrobolome50 /100 · in range54 /100 · in rangeexpected < 65Estrogen-recycling capacity.
Virulence factors · 1
fimD outer membrane usher99 potriviri/M · present68 potriviri/M · presentexpected absentVirulence factor detected.
Antibiotic resistance genes · 3
sul15.6 citiri/M · present9.6 citiri/M · presentexpected nedetectatResistance gene detected.
sul21.3 citiri/M · present7.6 citiri/M · presentexpected nedetectatResistance gene detected.
tet(O/M/O)4.9 citiri/M · presentresolved(resolved)expected nedetectatResistance gene detected.
Genetic predisposition · 2
FUT23.41 OR · risk variant2.48 OR · risk variantexpected reference genotypeReduced mucosal fucosylation
CYP2D61.51 OR · risk variant3.43 OR · risk variantexpected reference genotypeHigher exposure at standard dose